Sanofi (SNYNF) Other Non-Current Assets (2009 - 2026)
Sanofi (SNYNF) posted Other Non-Current Assets of $743.4 million for Q1 2026, up 207.05% sequentially from $242.1 million in Q4 2025, and down 94.85% YoY from $14.4 billion in Q1 2025.
Sanofi (SNYNF) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Other Non-Current Assets data on file, last reported at $743.4 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 94.85% year-over-year to $743.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $743.4 million (down 94.85% YoY) and the FY2025 annual result came in at $242.1 million, down 93.96% from the prior year.
- Other Non-Current Assets advanced to $743.4 million in Q1 2026 per SNYNF's latest filing, from $242.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $14.4 billion in Q1 2025, with the low at $161.3 million in Q3 2025.
- Average Other Non-Current Assets over 5 years is $3.8 billion, with a median of $3.5 billion recorded in 2023.
- Year-over-year, Other Non-Current Assets rose 29.59% in 2025 and sank 94.85% in 2026.
- Sanofi's Other Non-Current Assets stood at $3.2 billion in 2022, then gained by 9.65% to $3.5 billion in 2023, then climbed by 15.83% to $4.0 billion in 2024, then tumbled by 93.96% to $242.1 million in 2025, then soared by 207.05% to $743.4 million in 2026.
- Business Quant data shows SNYNF's Other Non-Current Assets at $743.4 million in Q1 2026, $242.1 million in Q4 2025, and $161.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.23 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.54 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 200.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | 743.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 743.42 Mn |
| Dec 31, 2025 | 242.12 Mn |
| Sep 30, 2025 | 161.33 Mn |
| Jun 30, 2025 | 4.65 Bn |
| Mar 31, 2025 | 14.44 Bn |
| Dec 31, 2024 | 4.01 Bn |
| Jun 30, 2024 | 3.59 Bn |
| Dec 31, 2023 | 3.46 Bn |
| Jun 30, 2023 | 3.26 Bn |
| Dec 31, 2022 | 3.16 Bn |
| Jun 30, 2022 | 3.53 Bn |
| Dec 31, 2021 | 3.58 Bn |
| Jun 30, 2021 | 3.25 Bn |
| Dec 31, 2020 | 3.26 Bn |
| Jun 30, 2020 | 3.34 Bn |
| Dec 31, 2019 | 110,688.77 |
| Jun 30, 2019 | 2.54 Bn |
| Dec 31, 2018 | 3.21 Bn |
| Sep 30, 2018 | 1.16 Mn |
| Jun 30, 2018 | 1.19 Mn |